AR030920A1 - Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones - Google Patents

Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones

Info

Publication number
AR030920A1
AR030920A1 ARP000106019A ARP000106019A AR030920A1 AR 030920 A1 AR030920 A1 AR 030920A1 AR P000106019 A ARP000106019 A AR P000106019A AR P000106019 A ARP000106019 A AR P000106019A AR 030920 A1 AR030920 A1 AR 030920A1
Authority
AR
Argentina
Prior art keywords
compositions
mellitus diabetes
preparing
treatment
conditions associated
Prior art date
Application number
ARP000106019A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR030920(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9927119.9A external-priority patent/GB9927119D0/en
Priority claimed from GBGB9927120.7A external-priority patent/GB9927120D0/en
Priority claimed from GB0013236A external-priority patent/GB0013236D0/en
Priority claimed from GB0013240A external-priority patent/GB0013240D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR030920A1 publication Critical patent/AR030920A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, que comprenden una tiazolidindiona, tal como 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona, clorhidrato de metformina y un vehículo farmacéuticamente aceptable, en donde la tiazolidindiona y el clorhidrato de metformina están cada uno dispersados dentro de su propio vehículo farmacéuticamente aceptable en la composicion farmacéutica. En estas composiciones, la inestabilidad de la 5[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazonidil-2,4-diona, tanto durante su preparacion como durante su almacenamiento, debido a la presencia del clorhidrato de metformina está inhibida o impedida ya que cada agente activo está dispersado dentro de su propio vehículo. También se dan a conocer procedimientos para preparar dichas composiciones.
ARP000106019A 1999-11-16 2000-11-15 Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones AR030920A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9927119.9A GB9927119D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GBGB9927120.7A GB9927120D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GB0013236A GB0013236D0 (en) 2000-05-31 2000-05-31 Novel composition and use
GB0013240A GB0013240D0 (en) 2000-05-31 2000-05-31 Novel composition and use

Publications (1)

Publication Number Publication Date
AR030920A1 true AR030920A1 (es) 2003-09-03

Family

ID=27447849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP000106019A AR030920A1 (es) 1999-11-16 2000-11-15 Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
ARP060105370A AR057970A2 (es) 1999-11-16 2006-12-05 Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060105370A AR057970A2 (es) 1999-11-16 2006-12-05 Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones

Country Status (40)

Country Link
US (1) US8236345B2 (es)
EP (3) EP1231918B1 (es)
JP (2) JP4865975B2 (es)
KR (1) KR100760063B1 (es)
CN (1) CN1222290C (es)
AP (1) AP1389A (es)
AR (2) AR030920A1 (es)
AT (1) ATE292466T1 (es)
AU (3) AU775654B2 (es)
BG (1) BG65616B1 (es)
BR (1) BR0015605A (es)
CA (1) CA2388846A1 (es)
CO (1) CO5300392A1 (es)
CZ (1) CZ302500B6 (es)
DE (1) DE60019329T2 (es)
DK (1) DK1231918T3 (es)
DZ (1) DZ3251A1 (es)
EA (1) EA004878B1 (es)
ES (1) ES2240199T3 (es)
HK (1) HK1049788B (es)
HR (1) HRP20020416B1 (es)
HU (1) HU229960B1 (es)
IL (3) IL149618A0 (es)
MA (1) MA25567A1 (es)
ME (1) ME00318B (es)
MX (1) MXPA02005005A (es)
MY (1) MY125516A (es)
NO (1) NO329926B1 (es)
NZ (1) NZ518946A (es)
OA (1) OA12513A (es)
PE (1) PE20011011A1 (es)
PL (1) PL200943B1 (es)
PT (1) PT1231918E (es)
RS (1) RS51343B (es)
SI (1) SI1231918T1 (es)
SK (1) SK286985B6 (es)
TW (1) TWI240626B (es)
UA (1) UA73150C2 (es)
UY (1) UY26439A1 (es)
WO (1) WO2001035941A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60129425T2 (de) * 2000-05-01 2008-04-17 Aeropharm Technology LLC, Dover Kernformulierung
AU2001273290B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising troglitazone and a biguanide
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
EP1515701B1 (en) * 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR101363679B1 (ko) * 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
KR101114808B1 (ko) 2003-01-29 2012-02-15 다케다 야쿠힌 고교 가부시키가이샤 피복 제제의 제조법
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
WO2006011397A1 (ja) * 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
WO2006118137A1 (ja) 2005-04-26 2006-11-09 Dainippon Sumitomo Pharma Co., Ltd. ビグアナイド系薬物を含有する粒状製剤
WO2007072992A2 (en) * 2005-12-22 2007-06-28 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
WO2008078390A1 (ja) 2006-12-26 2008-07-03 Fujitsu Limited データ圧縮装置およびデータ復元装置
ME01239B (me) 2007-02-01 2013-06-20 Takeda Pharmaceuticals Co Čvrsti preparat koji sadrži alogliptin i pioglitazon
CN101674811B (zh) 2007-02-09 2015-08-19 阿尔法制药有限公司 含有两种或更多种不同物理形态的活性药物成分的剂型
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
CN102177436B (zh) 2008-08-12 2015-05-13 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
FR2951945B1 (fr) * 2009-11-05 2013-08-09 Sanofi Aventis Composition pharmaceutique
PL2498758T3 (pl) * 2009-11-13 2019-02-28 Astrazeneca Ab Formulacje tabletek dwuwarstwowych
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
KR20140035331A (ko) 2011-01-07 2014-03-21 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP3106165B1 (en) 2011-01-10 2019-02-27 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
JP6175074B2 (ja) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
CN108451923A (zh) * 2018-05-31 2018-08-28 常州兰陵制药有限公司 盐酸二甲双胍速释胶囊及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4613596Y1 (es) * 1969-06-02 1971-05-14
DE2347531A1 (de) * 1973-09-21 1975-04-30 Hoechst Ag Arzneizubereitungen zur oralen diabetes-behandlung
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4999226A (en) 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
JPH0553521A (ja) 1991-08-28 1993-03-05 Mitsubishi Electric Corp オートトラツキング型ｃｒｔデイスプレイモニタ
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
GB2350319B (en) 1996-06-14 2001-01-10 Rue De Int Ltd Security printed device
TW522014B (en) 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
CN1230171C (zh) * 1997-06-18 2005-12-07 史密丝克莱恩比彻姆有限公司 用噻唑烷二酮和二甲双胍治疗糖尿病
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
DZ2937A1 (fr) 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
SI1131070T1 (sl) 1998-11-12 2008-12-31 Smithkline Beecham Plc Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina
US20040102486A1 (en) 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU1403501A (en) 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
US6461639B2 (en) 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6296874B1 (en) 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6451342B2 (en) 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6403121B1 (en) 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
GB0318824D0 (en) 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition

Also Published As

Publication number Publication date
TWI240626B (en) 2005-10-01
EA200200571A1 (ru) 2002-12-26
HUP0204122A3 (en) 2006-01-30
IL149618A (en) 2008-07-08
MA25567A1 (fr) 2002-10-01
US20070275054A1 (en) 2007-11-29
DE60019329D1 (de) 2005-05-12
EP1913945A3 (en) 2008-04-30
BG106747A (en) 2003-01-31
PT1231918E (pt) 2005-08-31
NO329926B1 (no) 2011-01-24
AU775654B2 (en) 2004-08-12
AP1389A (en) 2005-04-14
CO5300392A1 (es) 2003-07-31
KR20030019300A (ko) 2003-03-06
NO20022334L (no) 2002-07-09
MEP34008A (en) 2011-02-10
HK1049788B (zh) 2005-11-04
DK1231918T3 (da) 2005-08-01
PE20011011A1 (es) 2001-10-28
WO2001035941A2 (en) 2001-05-25
UY26439A1 (es) 2001-07-31
EP1520581A1 (en) 2005-04-06
JP4865975B2 (ja) 2012-02-01
MXPA02005005A (es) 2003-10-14
CA2388846A1 (en) 2001-05-25
JP2011252007A (ja) 2011-12-15
AU1404001A (en) 2001-05-30
PL200943B1 (pl) 2009-02-27
EP1913945A2 (en) 2008-04-23
PL355331A1 (en) 2004-04-19
IL190220A0 (en) 2008-11-03
EA004878B1 (ru) 2004-08-26
HRP20020416B1 (en) 2011-04-30
HU229960B1 (hu) 2015-03-30
JP5282130B2 (ja) 2013-09-04
NO20022334D0 (no) 2002-05-15
WO2001035941A8 (en) 2002-08-29
AP2002002505A0 (en) 2002-06-30
EP1231918A2 (en) 2002-08-21
WO2001035941A3 (en) 2002-05-23
EP1231918B1 (en) 2005-04-06
OA12513A (en) 2006-05-29
KR100760063B1 (ko) 2007-09-18
DZ3251A1 (fr) 2001-05-25
SK6792002A3 (en) 2002-09-10
SI1231918T1 (en) 2005-08-31
ME00318B (me) 2011-05-10
UA73150C2 (uk) 2005-06-15
MY125516A (en) 2006-08-30
AU2004226955B2 (en) 2008-08-28
ES2240199T3 (es) 2005-10-16
RS51343B (sr) 2011-02-28
AU2008207375A1 (en) 2008-09-11
JP2003514012A (ja) 2003-04-15
HK1049788A1 (en) 2003-05-30
HRP20020416A2 (en) 2004-08-31
ATE292466T1 (de) 2005-04-15
BR0015605A (pt) 2002-07-09
SK286985B6 (sk) 2009-08-06
BG65616B1 (bg) 2009-03-31
CN1414852A (zh) 2003-04-30
AR057970A2 (es) 2007-12-26
US8236345B2 (en) 2012-08-07
NZ518946A (en) 2003-10-31
CZ302500B6 (cs) 2011-06-22
IL149618A0 (en) 2002-12-01
DE60019329T2 (de) 2006-03-09
CN1222290C (zh) 2005-10-12
YU38802A (sh) 2005-03-15
HUP0204122A2 (hu) 2003-03-28
AU2004226955A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
AR030920A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
RU98117673A (ru) Фармкомпозиция для лечения и/или профилактики гипергликемии, соль малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси] бензил] тиазолидин-2, 4-диона или ее изомерная или таутомерная форма для лечения диабета ii типа
TW200640455A (en) Oral dosage form comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
RU2001131722A (ru) 5-[4-(6-Метокси-1-метил-1Н-бензимидазол-2-илметокси)бензил]-тиазолидин-2,4 -ди он гидрохлорид, обладающий гипогликемической активностью
RU2001127082A (ru) Производные аминов
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
UY25102A1 (es) Nueva composición para el tratamiento de diabetes mellitus
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
AR008198A1 (es) Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
PE99499A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
CO5271647A1 (es) Metodo para prevenir la diarrea
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
AP2003002737A0 (en) Tartrate salts of thiazolidinedione derivatives
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
HUP0301799A2 (hu) 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-hidrojodid alkalmazása diabetetes mellitus kezelésére, eljárás a vegyület előállítására és ezt tartalmazó gyógyszerkészítmény

Legal Events

Date Code Title Description
FG Grant, registration